NASDAQ
5.94USD
+0.36 (+6.45%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
157.6M
P/E
—
EPS
—
Beta
0.78
52W range
4.37-11.3
Day range
5.59–6.00
Open
5.59
Prev close
5.58
Volume
264.2K
Avg volume
309.4K
Dividend
0.00
IPO
2021-06-30
https://www.zacks.com/stock/news/2970652/cvrx-cvrx-reports-q2-loss-beats-revenue-estimates?cid=CS-STOCKNEWSAPI-FT-fundamental_analysis|yseop_template_4-2970652 · 8/7/2026-0.30
https://www.zacks.com/stock/news/2944183/cvrx-cvrx-moves-11-6-higher-will-this-strength-last?cid=CS-STOCKNEWSAPI-FT-tale_of_the_tape|daily_price_change_5%-2944183 · 6/29/2026+0.60
https://www.globenewswire.com/news-release/2026/05/20/3298899/0/en/cvrx-to-present-at-the-william-blair-46th-annual-growth-stock-conference.html · 5/20/2026+0.10
https://www.globenewswire.com/news-release/2026/04/09/3270998/0/en/CVRx-Inc-Investigated-by-the-Portnoy-Law-Firm.html · 4/9/2026-1.00
https://www.globenewswire.com/news-release/2026/03/03/3248869/1087/en/INVESTOR-ALERT-Pomerantz-Law-Firm-Investigates-Claims-On-Behalf-of-Investors-of-CVRx-Inc-CVRX.html · 3/3/2026
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cvrx-inc----cvrx-302693244.html · 2/20/2026-1.00
https://www.globenewswire.com/news-release/2026/01/30/3229745/0/en/CVRx-ALERT-Bragar-Eagel-Squire-P-C-is-Investigating-CVRx-Inc-on-Behalf-of-CVRx-Stockholders-and-Encourages-Investors-to-Contact-the-Firm.html · 1/30/2026-0.80
https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-cvrx-inc----cvrx-302672194.html · 1/29/2026-1.00
CVRx, Inc. is a commercial-stage medical technology company focused on innovating, producing, and bringing to market neuromodulation solutions designed for individuals battling cardiovascular diseases. Its principal offering, Barostim, is an advanced neuromodulation device specifically indicated to ameliorate symptoms for patients diagnosed with heart failure characterized by reduced ejection fraction, often referred to as systolic heart failure. The company employs a diverse distribution strategy, leveraging its internal sales force, alongside sales agents and independent distributors, to reach markets across the United States, Germany, the wider European continent, and other global territories. Incorporated in 2000, CVRx, Inc. is headquartered in Minneapolis, Minnesota.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
